

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Orkambi (ivacaftor/lumacaftor)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Orkambi (ivacaftor/lumacaftor)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Orkambi (ivacaftor/lumacaftor) may be approved if the following are met:

- I. Individual has a diagnosis of cystic fibrosis (CF); **AND**
- II. Individual is 2 years of age or older*; **AND**
- III. Mutation testing indicates individual has two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; **AND**
- IV. A copy of the CF mutation analysis test result must be provided.

Orkambi (ivacaftor/lumacaftor) may not be approved for the following:

- I. Concurrent use with Kalydeco (ivacaftor), Symdeko (tezacaftor/ivacaftor) or Trikafta (elexacaftor/tezacaftor/ivacaftor).

***NOTE:** All requests for California Medicaid individuals less than 21 years of age will be reviewed by the health plan.

State Specific Mandates		
CA	9/26/2015	Request from California Children's Services to have all requests for Orkambi in individuals less than 21 years of age to be reviewed by the health plan.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: March 27, 2020.

CRX-ALL-0578-20

PAGE 1 of 2 08/15/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
4. Simon RH. Cystic fibrosis: Overview of the treatment of lung disease. Last updated: March 10, 2020. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: March 24, 2020.
5. Simon RH. Cystic fibrosis: Treatment with CFTR modulators. Last updated: February 13, 2020. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: March 24, 2020.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.